Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOU064 (Remibrutinib) in Sjögren's Syndrome
NCT04035668Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of remibrutinib in Sjögren's syndrome, sponsored by Novartis. Started Jul 2019; status: terminated.
02
Drugs
remibrutinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT04035668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035668.